ClinicalTrials.gg
Drug

Sarilumab clinical trials

Also written REGN88, Kevzara® and SAR153191.

studies test it
46
open now
8
in phase 3
16
first study started
2007

How each study uses sarilumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sarilumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 May 2017 · KEVZARA · BLA 761037 (FDA, Drugs@FDA)
European Union
23 Jun 2017 · Kevzara · EMEA/H/C/004254 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sarilumab
26
SAR153191 (REGN88)
5
sarilumab SAR153191 (REGN88)
5
Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
2

Brand

Kevzara®
11

Development codes

REGN88
13
SAR153191
11

Studies by the year they started

46 studies that test it; most in 2020 (10)

Studies that test sarilumab, by start year
YearStudies
20071
20083
20107
20111
20121
20133
20142
20153
20162
20184
20193
202010
20212
20231
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
12
Phase 2
22
Phase 3
16
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 27 · Other 19

Sanofi (22) · Regeneron Pharmaceuticals (5) · M.D. Anderson Cancer Center (1) · Assistance Publique - Hôpitaux de Paris (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Stanford University (1) · Maimónides Biomedical Research Institute of Córdoba (1) · Maria del Rosario Garcia de Vicuña Pinedo (1)

Often tested with

Tested in the same studies.

Tocilizumab (3) · Cemiplimab (2) · Hydroxychloroquine (2) · Baricitinib (2) · Adalimumab (2) · Lopinavir-ritonavir drug combination (1) · Lopinavir (1) · Ritonavir (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test sarilumab.

Studies

Open first, then newest update. How each study uses sarilumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 46

See all 46 studies that test sarilumab →

Given beside what is tested · 13 — sarilumab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with sarilumab

Codes

What other systems call sarilumab · ClinicalTrials.gg INT000092

  • MeSH (NLM) C000592401sarilumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) NU90V55F8ISARILUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1923319Confirmed FDA, Wikidata
  • Wikidata Q7424081sarilumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152302SarilumabOne source FDA
  • DrugBank DB11767One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.